Simplified aztreonam dosing in patients with end stage renal disease: results of a Monte Carlo simulation [Clinical Therapeutics]

The manufacturer-labeled aztreonam dosing in patients with a creatinine clearance of <10 mL/min/1.73m² is complex. It is unknown if simpler post-hemodialysis dosing administered once daily or thrice weekly can reliably achieve pharmacodynamic goals. We found that 1 or 2 grams once daily post-hemodialysis had a >90% probability of target attainment up to an MIC of 4 or 8mg/L, respectively. Thrice weekly dosing should generally be avoided except in non-severe infections where the MIC is ≤0.5mg/L.

https://ift.tt/2N0KGE4